Acute HIV Studies at UNC

CID 0804: Longitudinal (CTRC 2134) – Acute HIV Longitudinal Study

POP: Individuals diagnosed with Acute HIV Infection
CALL: Francesca Prince, 919-966-8794 or 919-428-7612 or Caroline Baker, 919-966-2623

PHI 05: QD Therapy with Dolutegravir/Epzicom for Acute HIV Infection

Q: Treatment of Acute HIV Infection with one tablet once a day
POP: Acute HIV infection
MED: Fixed-dose combination of dolutegravir and epzicom
Substudy: Leukapheresis
DUR: 5 years (medication provided for 2 years)
CALL: Kristen Hancock, RN, 919-843-6848

A5354: Effect of Antiretroviral Treatment Initiated During Acute HIV-1 Infection on Measures of HIV-1 Persistence and on HIV-1-Specific Immune Responses


Timing of antiretroviral therapy (ART) during different stages of acute HIV-1 infection (AHI) will be predictive of the magnitude and characteristics of HIV-1 reservoirs, and the quantity and quality of HIV-1-specific immune responses at week 48.


Men and women 18 years and older with AHI.

Group 1: Fiebig I/II (non-reactive HIV-1 antibody)

Group 2: Fiebig III/IV (reactive HIV-1 antibody and negative or indeterminate results on the Western blot or Geenius HIV-1/HIV-2)

Group 3: Fiebig V (reactive HIV-1 antibody and positive Western blot or Geenius HIV-1/HIV-2 without p31 band)


The antiretroviral (ARV) regimen provided through the study is the single tablet regimen elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (EVG/COBI/FTC/TAF). Other non-study-provided ARV regimens will be allowed for participants who are pregnant, breastfeeding, or unable/unwilling to take EVG/COBI/FTC/TAF, or for participants whose local health care/primary care provider prefers starting a different initial ARV regimen.


Up to 72 weeks.


Kristen Hancock, RN, BSN, 919-843-6848 or Susan Pedersen, RN, 919-966-6713